Conference Coverage
Advertisement
An MDS HSPC signature generated from the model presents possible targets for treatment in patients with low-risk disease.
The study's results especially highlight potential aberrant gene regulation by ZMAT2 and SMARCD3.
The study showed a mortality risk reduction benefit in certain mutations while for others larger studies are needed.
Researchers noted that confirmation of this relationship in lower-risk disease would require a larger study.
Dr. Karine Tawagi speaks with Dr. Adam Brufsky about notable data presented at SABCS 2024.
Dr. Adam Brufsky provides an overview on the best treatments in metastatic TNBC space, including Trodelvy.
Drs. Karine Tawagi and Adam Brufsky discuss the challenges of navigating treatment in patients with mTNBC.
A study sought to assess if a treatment combination inhibits tumor growth and metastasis in TNBC.
Sacituzumab govitecan-related neutropenia can be effectively treated using G-CSF prophylaxis in patients with mTNBC.
Researchers argue from their findings that the 2023 criteria more accurately present the performance of ivosidenib in MDS.
The combination in a phase II trial produced high complete response rates in patients with newly diagnosed AML.
Researchers also analyzed baseline stem cells for insight into patient response versus non-response to the combination.
The combination was compared with decitabine monotherapy in a multicenter, open-label, RCT.
A study evaluated azacitidine combined with ipilimumab or nivolumab and triplet of these agents in treatment-naive MDS.
A study shows how how advancements in diagnostic tools and treatments for ATTR-CM have improved risk profiles.
A recent post-hoc analysis of the ATTRibute-CM trial shows the potential for acoramidis in treating ATTR-CM.
A study found an overall decline in surgical myectomy with ICD procedures since 2016.
Researchers sought to assess the rate of axillary pCR in TNBC patients.
Across several patient subgroups luspatercept was observed to produce longer durations of transfusion independence.
Adding pembrolizumab to conventional neoadjuvant cytotoxic chemotherapy may improve survival outcomes.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.